Biogen (NASDAQ: BIIB) will, this week, present data at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Barcelona, Spain, demonstrating the ...
The FINANCIAL — Biogen unveiled new TECFIDERA (dimethyl fumarate) research that reinforces its strong and sustained efficacy in newly diagnosed relapsing-remitting multiple sclerosis (RRMS) patients ...
Biogen Inc. (BIIB) is running a Phase 2 study called “A 2-Part, Multicenter, Randomized, Blinded, Active-Controlled Phase 2 Study to Sequentially Evaluate the Safety and Efficacy of BIIB091 ...
Generic Tecfidera is a treatment for patients with relapsing forms of multiple sclerosis, while generic Vimpat is used as monotherapy or adjunctive therapy in patients with partial onset seizures.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results